14548-50-6

Usage

Uses

Used in Pharmaceutical Research:
7-Chloro-3,4-dihydro-1H-quinolin-2-one is used as a compound of interest in pharmaceutical research due to its quinoline structure, which may exhibit biological and pharmacological activities. Its potential in this field is inferred from the known properties of related quinolines.
Used in Functional Materials Development:
7-Chloro-3,4-dihydro-1H-quinolin-2-one is also used as a candidate for the development of functional materials, given the possibility that its quinoline structure could contribute to the creation of materials with specific properties or applications. The exact nature of these applications remains to be explored due to the limited research on 7-CHLORO-3,4-DIHYDRO-1H-QUINOLIN-2-ONE.

Upstream product

• 20357-27-1 4-chloro-2-nitro-cinnamic acid 
• 6828-35-9 5-chloro-2-iodoaniline 
• 140-88-5 ethyl acrylate 
• 68716-47-2 2,4-dichlorophenylboronic acid 
• 79-06-1 2-propenamide 
• 231294-99-8 ethyl 3-(4-chloro-2-nitrophenyl)acrylate 
• 1060737-02-1 3-(2-amino-4-chlorophenyl)-propan-1-ol 
• 1375234-69-7 3-(2-amino-4-chlorophenyl)-2-propyn-1-ol 

Downstream Products

• 90562-35-9 7-chloro-1,2,3,4-tetrahydroquinoline 
• 131637-35-9 7-Chloro-1-{3-[4-(2-chloro-phenyl)-9-methyl-6H-1-thia-5,7,8,9a-tetraaza-cyclopenta[e]azulen-2-yl]-prop-2-ynyl}-3,4-dihydro-1H-quinolin-2-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Provided herein are novel heterocyclic compounds, for example, compounds having Formula I, I-P, II, lI-P, or III. Also provided herein are pharmaceutical compositions comprising the compounds and methods of using the same, for example, in inhibiting aldehyde dehydrogenases and/or for treating various cancers, cancer metastasis, type 2 diabetes, pulmonary arterial hypertension (PAH) or neointimal hyperplasia (NIH).

Visible-Light Induced C(sp2)?H Amidation with an Aryl–Alkyl σ-Bond Relocation via Redox-Neutral Radical–Polar Crossover

We report an approach for the intramolecular C(sp2)?H amidation of N-acyloxyamides under photoredox conditions to produce δ-benzolactams with an aryl-alkyl σ-bond relocation. Computational studies on the designed reductive single electron transfer strategy led us to identify N-[3,5-bis(trifluoromethyl)benzoyl] group as the most effective amidyl radical precursor. Upon the formation of an azaspirocyclic radical intermediate by the selective ipso-addition with outcompeting an ortho-attack, radical–polar crossover was then rationalized to lead to the rearomative ring-expansion with preferential C?C bond migration.

Discovery of tetrahydroquinolines and benzomorpholines as novel potent RORγt agonists

The retinoic acid receptor-related orphan receptor γt (RORγt) is an important nuclear receptor that regulates the differentiation of Th17 cells and production of interleukin 17(IL-17). RORγt agonists increase basal activity of RORγt and could provide a potential approach to cancer immunotherapy. Herein, hit compound 1 was identified as a weak RORγt agonist during in-house library screening. Changes in LHS core of 1 led to the identification of tetrahydroquinoline compound 6 as a partial RORγt agonist (max. act. = 39.3%). Detailed structure-activity relationship on substituent of the LHS core, amide linker and RHS arylsulfonyl moiety was explored and a novel series of tetrahydroquinolines and benzomorpholines was discovered as potent RORγt agonists. Tetrahydroquinoline compound 8g (EC50 = 8.9 ± 0.4 nM, max. act. = 104.5%) and benzomorpholine compound 9g (EC50 = 7.5 ± 0.6 nM, max. act. = 105.8%) were representative compounds with high RORγt agonistic activity in dual FRET assay, and they showed good activity in cell-based Gal4 reporter gene assay and Th17 cell differentiation assay (104.5% activation at 300 nM of 8g; 59.4% activation at 300 nM of 9g). The binding modes of 8g and 9g as well as the two RORγt inverse agonists accidentally discovered were also discussed.

RETRACTED ARTICLE: Site-selective enzymatic C-H amidation for synthesis of diverse lactams

A major challenge in carbon?hydrogen (C?H) bond functionalization is to have the catalyst control precisely where a reaction takes place. In this study, we report engineered cytochrome P450 enzymes that perform unprecedented enantioselective C?H amidation reactions and control the site selectivity to divergently construct b-, g-, and d-lactams, completely overruling the inherent reactivities of the C?H bonds. The enzymes, expressed in Escherichia coli cells, accomplish this abiological carbon?nitrogen bond formation via reactive iron-bound carbonyl nitrenes generated from nature-inspired acyl-protected hydroxamate precursors. This transformation is exceptionally efficient (up to 1,020,000 total turnovers) and selective (up to 25:1 regioselectivity and 97%, please refer to compound 2v enantiomeric excess), and can be performed easily on preparative scale.

ALDOSTERONE SYNTHASE INHIBITORS

This invention relates to tricyclic triazole analogues of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.

The synthesis of N-heterocycles via copper/TEMPO catalysed aerobic oxidation of amino alcohols

N-Heterocycles can be prepared using alcohol oxidation as a key synthetic step. Herein we report studies exploring the potential of Cu/TEMPO as an aerobic oxidation catalyst for the synthesis of substituted indoles and quinolines.

The tandem reaction combining radical and ionic processes: an efficient approach to substituted 3,4-dihydroquinolin-2-ones

3,4-Dihydroquinolin-2-ones are of great importance in the areas of pharmaceuticals. However, the direct intramolecular radical cyclizations of the corresponding amide compounds favor 5-exo products 2. Reports on the radical cyclization reactions producing

SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES

The invention relates to substituted acids of formula (I), where T,W,X,Y,Z, R1 and R2 as defined in the claims, as useful pharmaceutical compounds for treating asthma and rhinitis, pharmaceutical compositions containing them, and a processes for their preparation.

Heteroaryl piperazine antipsychotic agents

Compounds of the formula STR1 and pharmaceutical compositions comprising them, wherein R1, Z, X, W and Y are as defined below. The compounds are useful in the treatment of psychosis and anxiety.

Heterocyclic aldose reductase inhibitors and methods of using them

The invention relates to new compounds of the formula: STR1 Aldose reductase inhibitors. Treatment of certain complications of diabetes.